Bulk Pharmaceutical API Sources for temazepam

Bulk Pharmaceutical API Sources for temazepam

Vendor	Vendor Homepage	Vendor Sku	API Url
ChemExper Chemical Directory		jj}Pb@AJCdDQdTRTtRTTRRMNZ\dl@PuATBD@@@
NovoSeek		5391
ABI Chem		AC1L1K92

Bulk Active Pharmaceutical Ingredient (API) Sources for Temazepam

Last updated: February 19, 2026

This report identifies and analyzes key global suppliers of bulk active pharmaceutical ingredient (API) for temazepam. It focuses on manufacturers with established production capabilities, regulatory compliance, and significant market presence. The analysis prioritizes suppliers with demonstrated capacity for consistent quality and volume, essential for pharmaceutical development and commercialization.

Who Are the Leading Global Bulk API Manufacturers for Temazepam?

The global supply of temazepam bulk API is primarily concentrated among a select group of manufacturers, predominantly located in India and China, with some presence in Europe. These companies operate under stringent regulatory oversight, including Good Manufacturing Practices (GMP) standards mandated by major health authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Table 1: Key Global Temazepam API Manufacturers

Manufacturer Name	Country of Origin	Primary Markets Served	Regulatory Approvals (Examples)
Sun Pharmaceutical Industries Ltd.	India	Global (including US, Europe)	US FDA, EMA, WHO GMP
Dr. Reddy's Laboratories Ltd.	India	Global (including US, Europe)	US FDA, EMA, TGA
Aurobindo Pharma Ltd.	India	Global (including US, Europe)	US FDA, EMA, PMDA
Cipla Ltd.	India	Global (including US, Europe)	US FDA, EMA, Health Canada
Torrent Pharmaceuticals Ltd.	India	Global (including US, Europe)	US FDA, EMA
Alkem Laboratories Ltd.	India	Global (including US, Europe)	US FDA, EMA
Zhejiang NHU Co., Ltd.	China	Global	US FDA, EMA
Changzhou Qiaosheng Pharmaceutical Co., Ltd.	China	Global	US FDA, EMA
Novacyl (part of Seqens Group)	France	Europe, North America	EMA, US FDA

These manufacturers differentiate themselves through their regulatory track record, production scale, and commitment to quality control. For instance, companies like Sun Pharmaceutical and Dr. Reddy's Laboratories have consistently invested in expanding their API manufacturing capacity and broadening their regulatory certifications, enabling them to supply to highly regulated markets.

What are the Regulatory Requirements for Temazepam API Supply?

Supplying temazepam API to pharmaceutical companies requires adherence to a comprehensive set of regulatory standards to ensure product safety, efficacy, and quality. Key regulatory considerations include:

• Good Manufacturing Practices (GMP): All manufacturing facilities must comply with cGMP regulations as defined by the FDA (21 CFR Parts 210 & 211) and equivalent international standards like the EMA's EudraLex Volume 4. This covers all aspects of production, from raw material sourcing to finished API packaging.
• Drug Master Files (DMFs): Manufacturers typically submit DMFs to regulatory agencies. A DMF is a submission to regulatory authorities (like the FDA) that contains detailed information about the facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows regulatory bodies to review confidential API information without it being directly accessible to the drug product applicant.
• Certificate of Analysis (CoA): Each batch of API must be accompanied by a CoA that details its physical and chemical characteristics, purity, and assay results, confirming it meets predefined specifications.
• Impurity Profiling: Detailed analysis and control of process-related impurities and degradation products are critical. Regulatory agencies expect thorough characterization and qualification of impurities above certain thresholds.
• Stability Studies: Comprehensive stability data demonstrating the API's shelf-life under specified storage conditions is mandatory.
• Traceability and Supply Chain Security: Robust systems for tracking raw materials and finished API batches are essential to prevent counterfeiting and ensure supply chain integrity.
• Controlled Substance Regulations: As temazepam is a Schedule IV controlled substance in the United States, API manufacturers and distributors must comply with regulations set by the Drug Enforcement Administration (DEA). This involves stringent security measures, record-keeping, and quota management. Similar controls exist in other jurisdictions.

The ability of a supplier to demonstrate compliance through audits, certifications, and documentation is a critical factor in selection.

How Does Production Capacity and Scale Influence API Sourcing?

Production capacity and scale are direct determinants of a supplier's ability to meet the volume requirements of pharmaceutical clients, from clinical trial quantities to commercial production. Manufacturers with large-scale, dedicated production lines can offer cost efficiencies and ensure a consistent supply chain.

• Scalability: Suppliers must demonstrate the ability to scale production up or down based on market demand, a critical factor for new drug approvals and product launches.
• Batch Consistency: Larger manufacturers often have more established process controls, leading to greater batch-to-batch consistency, which is vital for maintaining product quality and regulatory compliance.
• Cost of Goods Sold (COGS): Economies of scale generally translate to lower per-unit production costs. Companies that produce large volumes of temazepam API can often offer more competitive pricing, impacting the overall profitability of the final drug product.
• Lead Times: Established, high-capacity manufacturers typically have more predictable lead times for API delivery, allowing for better inventory management and production planning for drug product manufacturers.

Indian manufacturers, in particular, have established significant global capacity for many APIs, including benzodiazepines like temazepam, driven by a favorable cost structure and a strong base of skilled scientific and technical personnel.

What are the Quality Control and Assurance Protocols for Temazepam API?

Robust quality control (QC) and quality assurance (QA) systems are paramount for temazepam API suppliers. These protocols ensure that each batch of API meets stringent specifications and regulatory requirements.

Key QC/QA elements include:

• Analytical Testing:
  • Identity: Confirmation of the chemical structure using techniques like Infrared (IR) spectroscopy, Nuclear Magnetic Resonance (NMR) spectroscopy, and Mass Spectrometry (MS).
  • Purity: Determination of impurity levels using High-Performance Liquid Chromatography (HPLC), Gas Chromatography (GC), and Thin-Layer Chromatography (TLC). Limits for specified and unspecified impurities are rigorously defined.
  • Assay: Quantitative determination of temazepam content, typically by HPLC or titration. Specifications usually require an assay of 98.0% to 102.0% on an anhydrous basis.
  • Related Substances: Quantification of known and unknown impurities that may arise from synthesis or degradation.
  • Residual Solvents: Analysis for residual organic solvents used in the manufacturing process, adhering to ICH Q3C guidelines.
  • Water Content: Determination of moisture content using Karl Fischer titration.
  • Heavy Metals: Testing for the presence of heavy metal contaminants.
  • Particle Size Distribution: For solid dosage forms, control of particle size can be critical for dissolution and bioavailability.
• Process Validation: Rigorous validation of all manufacturing processes to ensure they consistently produce API meeting predefined specifications.
• Change Control: A formal system for managing any proposed changes to raw materials, manufacturing processes, equipment, or analytical methods.
• Deviations and CAPA (Corrective and Preventive Actions): A system for documenting and investigating deviations from standard operating procedures and implementing CAPA to prevent recurrence.
• Internal Audits and Regulatory Inspections: Regular internal audits and successful responses to audits by regulatory agencies (FDA, EMA) and customers.

Companies like Novacyl, a European producer, often emphasize their integrated manufacturing and stringent quality systems developed within the European regulatory framework.

What are the Price and Availability Trends for Temazepam API?

The pricing and availability of temazepam API are influenced by raw material costs, manufacturing efficiency, regulatory compliance costs, and global supply-demand dynamics.

• Raw Material Costs: The precursors used in the synthesis of temazepam can fluctuate in price, directly impacting API production costs.
• Manufacturing Location: API manufactured in regions with lower labor and operational costs (e.g., India) often presents a more competitive price point compared to API produced in Western Europe or North America.
• Regulatory Hurdles: The cost of maintaining GMP compliance, conducting stability studies, and preparing regulatory filings adds to the overall cost of API production.
• Market Competition: A higher number of qualified suppliers can lead to more competitive pricing. Conversely, consolidation or limited qualified suppliers can exert upward pressure on prices.
• Global Demand: Demand for temazepam API is linked to the market for finished temazepam drug products. Factors affecting this include prescription rates, generic competition, and the emergence of alternative therapies.

Generally, Indian API manufacturers are known for offering competitive pricing due to economies of scale and operational efficiencies. However, quality, regulatory compliance, and supply chain reliability remain paramount considerations that can influence the ultimate sourcing decision, sometimes justifying a higher price point for greater assurance. The controlled substance nature of temazepam also adds a layer of complexity to its availability and distribution, potentially impacting pricing and lead times.

Key Takeaways

• Global temazepam API supply is concentrated among manufacturers in India and China, with a notable European presence.
• Key suppliers possess significant regulatory compliance, including US FDA and EMA GMP certifications.
• Stringent adherence to GMP, DMF filings, and impurity control are critical for market access.
• Production capacity and scale directly impact cost-effectiveness and the ability to meet commercial demands.
• Robust quality control and assurance protocols are non-negotiable for ensuring API safety and efficacy.
• Pricing is influenced by raw material costs, manufacturing location, and market competition, with Indian manufacturers often offering competitive rates.

Frequently Asked Questions

1. What is the typical minimum order quantity (MOQ) for temazepam API from major manufacturers? MOQs can vary significantly based on the manufacturer and current production schedules, but typically range from kilograms to hundreds of kilograms for bulk API orders.
2. Are there specific challenges in sourcing temazepam API due to its controlled substance status? Yes, temazepam is a controlled substance, requiring specialized licenses, stringent security, meticulous record-keeping, and adherence to quota systems by both manufacturers and distributors.
3. How can a pharmaceutical company assess the reliability of a temazepam API supplier's supply chain? Reliability can be assessed through site audits, review of historical delivery performance, checks on inventory management practices, and verification of contingency plans for supply disruptions.
4. What are the key differences in quality standards between API sourced from India versus Europe? While both regions must meet GMP standards, European manufacturers may emphasize greater integration of quality systems within their regional regulatory framework, potentially leading to different approaches in documentation and auditing nuances, though the fundamental quality requirements are globally standardized.
5. Does the synthesis route used by an API manufacturer impact the final product quality or regulatory approval? Yes, the synthesis route can influence the impurity profile, potential for environmental impact, and overall cost. Regulatory agencies scrutinize the chosen synthesis route and its validation as part of the drug application review.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from [FDA Website] [2] European Medicines Agency. (n.d.). EudraLex - The Rules Governing Medicinal Products in the European Union. Volume 4 - Good Manufacturing Practice. Retrieved from [EMA Website] [3] U.S. Drug Enforcement Administration. (n.d.). Controlled Substances Act. Retrieved from [DEA Website] [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1995). ICH Harmonised Tripartite Guideline Impurities: Guidelines for Residual Solvents Q3C(R6). Retrieved from [ICH Website]